Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) stock is surging on Wednesday, without any news to justify the movement. Session volume stands at 69.3 million versus the average volume of 26.9 million, ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...

Air pollution in Hanoi is causing widespread health problems and productivity losses. While the government is moving to phase out petrol vehicles and curb urban emissions, much of the city’s pollution ...

Abstract: This paper focuses mainly on the time and space complexity computation of the Tower of Hanoi, this mathematical game or puzzle is a well-known problem for its exponential time consumption, ...

RXRX stock looks like a deep-value growth bet at just $5 and change. Though the technology is exciting, I’m not rushing into shares just yet. Nvidia made early investors rich, but there is a new class ...

The city vibe is… cultural, historical and traditional. Hanoi is Vietnam’s capital, a sophisticated, thousand-year-old city whose heartbeat emanates from the Old Quarter. Here, 19th-century ...

Photos of the Vietnamese capital, home to almost 9 million people, show the environmental cost of the Southeast Asian nation’s explosive growth. HANOI, Vietnam — Hanoi has no horizon. Blocky apartment ...

During the last three months, 4 analysts shared their evaluations of Recursion Pharmaceuticals (NASDAQ:RXRX), revealing diverse outlooks from bullish to bearish. The table below provides a snapshot of ...

This week, I had to make one of the most difficult decisions of my career: saying goodbye to 20% of the team at Recursion. The process was extraordinarily painful, and the costs were heartbreakingly ...